Interleukin-10 作为对小鼠肝细胞癌树突状细胞免疫治疗反应的标志物。
Interleukin-10 as a marker for response to dendritic cells-dribbles immunotherapy in hepatocellular carcinoma, a mice model.
发表日期：2024 Jul
作者：
Alia A El Shahawy, Awny A Gawish, Takwa E Meawed, Naglaa M Ahmed, Alshymaa A Ahmed, Amina A Abdelhadi
来源：
CYTOKINE & GROWTH FACTOR REVIEWS
摘要：
癌症免疫疗法是癌症治疗中一种很有前途的策略，包括肝细胞癌（HCC）。本实验研究旨在评估白细胞介素 10 (IL-10) 作为生物标志物，用于监测肿瘤源性自噬体疫苗在 HCC 诱导小鼠中诱导抗肿瘤免疫的反应。该研究在 56 只 BALB/c 小鼠身上进行；分为 20 个正常细胞和 36 个用人肝癌细胞系 (HepG2) 诱导的癌症细胞。后者分为阳性对照组（n=6）和治疗组（n=30），治疗组又分为 3 个亚组：（A）仅用树突状细胞（DC）疫苗治疗，（B）用仅命名为 Dribbles 的疫苗，(C) 用 DC 加 Dribbles 进行处理。免疫治疗后评估血清IL-10。 DC加Dribbles疫苗接种的小鼠肿瘤体积缩小的平均百分比显着优于DC和Dribbles组（分别为p=0.013和p=0.043）。不同免疫治疗组之间IL-10水平存在统计学显着差异(p=0.0003)。阳性对照组的平均IL-10水平为19.50 pg/ml，Dribbles组为13 pg/ml，DC组为10 pg/ml，DC加Dribbles组为3.50 pg/ml。我们得出的结论是，DC-Dribbles 疫苗在减少 HCC 发展和提高生存率方面比单独使用 Dribbles 或单独使用 DC 具有显着的功效。 IL-10 是免疫治疗后反应的预测生物标志物。版权所有 © 埃及免疫学家协会。
Cancer immunotherapy is a promising strategy in cancer management, including hepatocellular carcinoma (HCC). This experimental study aimed to evaluate interleukin-10 (IL-10) as a biomarker for monitoring the response of tumor-derived autophagosomes vaccine in inducing antitumor immunity in HCC induced mice. It was conducted on 56 BALB/c mice; divided into 20 normal and 36, cancer induced with human liver cancer cell line (HepG2) cells. The latter group was subdivided into a positive control group (n=6) and a treated group (n=30), that was subdivided into 3 subgroups: (A) treated with dendritic cells (DC) vaccine only, (B) treated with vaccine named Dribbles only, and (C) treated with DC plus Dribbles. Serum IL-10 was assessed after immunotherapy. The mean percentage of tumor volume reduction in mice vaccinated by DC plus Dribbles was significantly superior to DC and Dribbles groups (p= 0.013, and p= 0.043, respectively). There was a statistically significant difference in IL-10 levels between different immunotherapy groups (p= 0.0003). As the mean IL-10 level was 19.50 pg/ml for the positive control group, 13 pg/ml for Dribbles group, 10 pg/ml for DCs group and 3.50 pg/ml for DCs plus Dribbles group. We conclude that DC-Dribbles vaccine has a remarkable efficacy superior to either Dribbles alone or DC alone in the decline of HCC development and survival improvement. IL-10 is a predictive biomarker for response after immunotherapy.Copyright© by the Egyptian Association of Immunologists.